Literature DB >> 11599735

Non-standard biological activities of lipopolysaccharide from Helicobacter pylori.

Naohiro Matsuyama, Teruo Kirikae1, Fumiko Kirikae1, Masahito Hashimoto1, Ken-Ichi Amano1, Shunji Hayashi1, Yoshikazu Hirai1, Tatsuya Kubota1, Masayasu Nakano1.   

Abstract

As assessed by the lipopolysaccharide (LPS)-specific chromogenic Limulus amoebocyte lysate (LAL) assay, Helicobacter pylori LPS extracted by the phenol-water procedure showed full potency to coagulate LAL, as did LPS from Salmonella minnesota and Escherichia coli. However, pretreatment of H. pylori LPS with polymyxin B, which easily destroys the endotoxic activity of enterobacterial LPS/lipid A, had little effect on the LAL coagulation activity, although the same treatment of E. coli LPS markedly diminished its activity. The H. pylori LPS induced very weak production of nitric oxide (NO) or tumour necrosis factor (TNF) by murine macrophages and TNF by human peripheral whole blood in vitro in comparison with S. minnesota LPS. These findings indicate that H. pylori LPS has the unique endotoxic characteristic of retaining full LAL coagulation activity with polymyxin B resistance, despite losing its endotoxic potencies such as the ability to induce NO and TNF production.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11599735     DOI: 10.1099/0022-1317-50-10-865

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  9 in total

Review 1.  The Immune Battle against Helicobacter pylori Infection: NO Offense.

Authors:  Alain P Gobert; Keith T Wilson
Journal:  Trends Microbiol       Date:  2016-02-22       Impact factor: 17.079

2.  Impact of Helicobacter pylori virulence factors and compounds on activation and maturation of human dendritic cells.

Authors:  Katharina Kranzer; Liane Söllner; Michael Aigner; Norbert Lehn; Ludwig Deml; Michael Rehli; Wulf Schneider-Brachert
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway.

Authors:  Susu M Zughaier; Yih-Ling Tzeng; Shanta M Zimmer; Anup Datta; Russell W Carlson; David S Stephens
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Helicobacter pylori lipopolysaccharide: biological activities in vitro and in vivo, pathological correlation to human chronic gastritis and peptic ulcer.

Authors:  Yi-Hui Luo; Jie Yan; Ya-Fei Mao
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

5.  Helicobacter pylori induces transendothelial migration of activated memory T cells.

Authors:  Karin Enarsson; Mikael Brisslert; Steffen Backert; Marianne Quiding-Järbrink
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Bioactivity and immunological evaluation of LPS from different serotypes of Helicobacter pylori.

Authors:  Davoud Esmaeilli; Ashraf Mohabati Mobarez; Ali Hatef Salmanian; Ahmad Zavaran Hosseini
Journal:  Iran J Microbiol       Date:  2013-06

7.  Oral administration of Pantoea agglomerans-derived lipopolysaccharide prevents metabolic dysfunction and Alzheimer's disease-related memory loss in senescence-accelerated prone 8 (SAMP8) mice fed a high-fat diet.

Authors:  Yutaro Kobayashi; Hiroyuki Inagawa; Chie Kohchi; Kimiko Kazumura; Hiroshi Tsuchiya; Toshiyuki Miwa; Katsuichiro Okazaki; Gen-Ichiro Soma
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

8.  A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients.

Authors:  Xiaolin Pan; Yuqin Li; Jin Feng; Xiaoyong Wang; Bo Hao; Ruihua Shi; Guoxin Zhang
Journal:  BMC Cancer       Date:  2013-03-18       Impact factor: 4.430

9.  Oral administration of Pantoea agglomerans-derived lipopolysaccharide prevents development of atherosclerosis in high-fat diet-fed apoE-deficient mice via ameliorating hyperlipidemia, pro-inflammatory mediators and oxidative responses.

Authors:  Yutaro Kobayashi; Hiroyuki Inagawa; Chie Kohchi; Kimiko Kazumura; Hiroshi Tsuchiya; Toshiyuki Miwa; Katsuichiro Okazaki; Gen-Ichiro Soma
Journal:  PLoS One       Date:  2018-03-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.